Yunzhao Wu
Has grant
Research Associate
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Detection and characterisation of p53 aggregates in liquid biopsy with ultrasensitive immunoassays
Open Date: 2025-01-01
Close Date: 2027-01-01
Articles (13)
Year:
2026
Year:
2026
A new assay leverages the small molecule BF-79-2, instead of antibodies, to specifically capture and detect α-synuclein aggregates at picomolar levels in biofluids, enhancing versatility for biomarker disease diagnostics.
Year:
2025
Tau, a microtubule‐associated protein, plays a critical role in maintaining neuronal structure and function. However, in neurodegenerative diseases such as Alzheimer's disease and other tauopathies, tau misfolds and aggregates into oligomers and fibrils, leading to neuronal damage. Tau oligomers are increasingly recognised as the most neurotoxic species, inducing synaptic dysfunction and contributing to disease progression. Detecting these early‐stage aggregates is challenging due to their low concentration and high heterogeneity in biological samples. Traditional methods such as immunostaining and enzyme‐linked immunosorbent assay (ELISA) lack the sensitivity and specificity to reliably detect small tau aggregates. Advanced single‐molecule approaches, including single‐molecule fluorescence resonance energy transfer (smFRET) and single‐molecule pull‐down (SiMPull), offer improved sensitivity for studying tau aggregation at the molecular level. These emerging tools provide critical insights into tau pathology, enabling earlier detection and characterisation of disease‐relevant aggregates, thereby offering potential for the development of targeted therapies and diagnostic approaches for tauopathies.
Year:
2025
Year:
2025
The double-helix point-spread function (DH-PSF) is one of the most used PSFs for large depth-of-field 3D single-molecule localisation microscopy. Due to its popularity, many algorithms have been developed to analyse experimental DH-PSF data, either based on dedicated DH-PSF fitting or on generalised PSF fitting, typically using cubic splines. We show here that the most popular implementations of both these approaches have limitations in terms of localisation performance, processing speed or user-friendliness. To overcome some of these limitations, we have developed a new analytical approach for DH-PSF fitting based on unmixing (DHPSFU) of fitted localisation data using distance pairing. We compare DHPSFU with two popular algorithms, SMAP and EasyDHPSF, using realistic simulated datasets based on experimental data, to show that our algorithm achieves the highest Jaccard index (DHPSFU: 0.98; SMAP: 0.91; EasyDHPSF: 0.85) and fastest CPU-based processing speed (DHPSFU: 6,800 locs/s; SMAP: 2,500 locs/s; EasyDHPSF: 63 locs/s). We also show that our algorithm achieves the best resolution when imaging the cellular plasma membrane of Jurkat T cells (DHPSFU: 140 nm, EasyDHPSF: 162 nm, SMAP: 165 nm). We have incorporated DHPSFU as a Fiji plugin and provide Matlab and Python scripts for user customisation.
Year:
2025
Background The tumour-suppressor protein p53 can form amyloid aggregates resulting in loss of tumour-suppressing functions and leading to tumour formation. The detection of p53 aggregates in cancer cells has been demonstrated but these aggregates have not been detected in liquid biopsies to date, due to the lack of sufficiently sensitive methods. Methods We developed an ultrasensitive immunoassay based on the single-molecule array (SiMoA) technology to detect p53 aggregates in plasma, based on antibody capture of the aggregates. We confirmed that the assay detects p53 aggregates using super-resolution imaging. We then investigated the p53 aggregate concentrations in the plasma of 190 pre-surgery glioblastoma (GB) patients and 22 controls using this assay. Results We found that the plasma p53 aggregate levels are significantly elevated in pre-surgery GB patients’ plasma compared to controls. Longitudinal study further reveals that p53 aggregate levels may increase before GB recurrence and decrease following treatment. We also observed raised p53 aggregate concentrations in the plasma of cancer patients with brain metastases. Conclusions This study demonstrates the detection of p53 aggregates in liquid biopsies. Our findings highlight the potential of p53 aggregates as a novel biomarker for glioblastoma.
Year:
2025
Year:
2025
INTRODUCTION The monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab were developed for the treatment of Alzheimer's disease (AD). METHODS We used single‐molecule detection and super‐resolution imaging to characterize the binding of these antibodies to diffusible amyloid beta (Aβ) aggregates generated in ‐ vitro and harvested from human brains. RESULTS Lecanemab showed the best performance in terms of binding to the small‐diffusible Aβ aggregates, affinity, aggregate coating, and the ability to bind to post‐translationally modified species, providing an explanation for its therapeutic success. We observed a Braak stage–dependent increase in small‐diffusible aggregate quantity and size, which was detectable with Aducanumab and Gantenerumab, but not Lecanemab, showing that the diffusible Aβ aggregates change with disease progression and the smaller aggregates to which Lecanemab preferably binds exist at higher quantities during earlier stages. DISCUSSION These findings provide an explanation for the success of Lecanemab in clinical trials and suggests that Lecanemab will be more effective when used in early‐stage AD. Highlights Anti amyloid beta therapeutics are compared by their diffusible aggregate binding characteristics. In‐vitro and brain‐derived aggregates are tested using single‐molecule detection. Lecanemab shows therapeutic success by binding to aggregates formed in early disease. Lecanemab binds to these aggregates with high affinity and coats them better.
Year:
2025
Live-cell imaging of cell surface topography and intracellular architecture is essential for understanding cellular function. However, conventional approaches often involve trade-offs between resolution, invasiveness, and volumetric coverage. Here, we present an integrated Scanning Ion Conductance Microscope and single-objective Oblique Plane Microscope (SICM-OPM) system that enables simultaneous non-contact topographical imaging and volumetric fluorescence imaging within the same live cell. Beyond correlative live imaging, the platform supports nanomechanical mapping with tens-of-nanometres resolution, fluorescence-guided localised molecular delivery via the SICM, and benefits from reduced photobleaching due to light-sheet excitation. We demonstrate this platform’s capabilities by visualising imipramine-induced T-tubule remodelling in live cardiomyocytes, revealing subsurface detubulation while surface morphology remains preserved. Additionally, we show precision delivery of fluorescent cargos—including dextrans and α-synuclein—into diatom and mammalian cells, alongside localised stiffness mapping to evaluate mechanical responses. We believe this technique opens new avenues for correlative structural, functional, and biophysical studies in live cells, with broad relevance to cell biology, neurodegeneration, and mechanobiology.
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Collaborators (15)
Wenzhi Hong
PDRA
Imperial College London
Hao Luo
Shanghai Jiao Tong University
Hu Lei
Shanghai Jiao Tong University
Julia Gorelik
Professor
Imperial College London
Francesco Antonio Aprile
Associate Professor in Biological Chemistry
Imperial College London
HADIA ALMAHLI
Lecturer (R&T)
Bangor University
Andriy Shevchuk
Associate Professor
Imperial College London
Steven F. Lee
Professor of Biophysical Chemistry
University of Cambridge
Maarten Dewilde
Professor
KU Leuven
David Klenerman
University of Cambridge
John S H Danial
University of St Andrews
Matthew Cheetham
PDRA
University of Cambridge
Aleks Ponjavic
University of Leeds
Timothy Chisholm
University of Cambridge
Gonçalo Bernardes
Professor of Chemical Biology
University of Cambridge Department of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.